Product Reports Resources Pricing Login Book a demo

Alder Biopharmaceuticals

Biotech & Life Sciences · Bothell, United States · Founded 2004 · IPO 2014

A biopharmaceutical company, Alder uses its proprietary technologies to uniquely identify, develop, produce and market its own antibody therapeutics MoreLess

Alder BioPharmaceuticals, accessible via alderbio.com, is a dynamic startup focused on developing innovative treatments for brain diseases. The company operates in the biopharmaceutical sector, which involves creating drugs and therapies derived from biological sources to treat medical conditions. Alder BioPharmaceuticals primarily serves patients suffering from neurological disorders, including but not limited to migraines and other chronic brain conditions.

The market Alder BioPharmaceuticals operates in is highly specialized and competitive, targeting a global audience with a significant presence in regions such as North America, Europe, and Asia. The company’s business model revolves around extensive research and development (R&D) to discover new treatments, followed by clinical trials to ensure safety and efficacy. Once a treatment is approved by regulatory bodies, Alder BioPharmaceuticals moves to the commercialization phase, where it partners with healthcare providers and pharmaceutical distributors to bring its products to market.

Revenue generation for Alder BioPharmaceuticals primarily comes from the sale of its approved therapies. Additionally, the company may engage in licensing agreements, where it allows other pharmaceutical companies to use its patented technologies in exchange for royalties or upfront payments. This dual approach of direct sales and licensing helps diversify its income streams and mitigate risks associated with drug development.

Alder BioPharmaceuticals is committed to reducing the stigma surrounding brain diseases by sharing true patient stories through its platform, The Lundbeck Magazine. This initiative not only raises awareness but also fosters a supportive community for those affected by neurological conditions.

In summary, Alder BioPharmaceuticals is a forward-thinking company dedicated to improving the lives of patients with brain diseases through innovative treatments and a strong focus on research and development.

Keywords: Biopharmaceuticals, Neurological Disorders, Brain Diseases, Research, Development, Clinical Trials, Commercialization, Licensing, Patient Stories, Global Market.

Valuation $1.95B
Revenue $1.6M
Total funding $100–500M

Talent graph

Alder Biopharmaceuticals's talent

Book a demo to see the people
Team profiled 14 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

8 investors on Alder Biopharmaceuticals's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Series A 3 investors entered at this stage
Sevin Rosen Funds
HIG Capital
H.I.G. HealthBridge
Series B+ 5 investors entered at this stage
TPG
Delphi Ventures
TPG Biotech
Novo Ventures
Redmile Group

Global footprint

Where Alder Biopharmaceuticals has talent and traffic

Workforce by country
🇺🇸 United States · Bothell HQ
Book a demo for the full country breakdown

Patent intelligence

Alder Biopharmaceuticals’s patent portfolio

Estimated portfolio value
$195M

38 active families in the valuation dataset.

Source: Dealroom Patent Intelligence · PatSnap. Portfolio estimates and the family records below have different coverage.

Compare patent portfolios across companies →

Market sentiment

What the market is saying about Alder Biopharmaceuticals

An AI-synthesized read of the highest-engagement posts about Alder Biopharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Alder Biopharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.